After detecting HER2+EVs released from breast cancer cells in vitro, we used flow cytometry to analyse EVs in plasma from breast cancer patients (clinical data summarised in Table II) without prior enrichment by ultracentrifugation. This evidence concerns the gene ERBB2 and breast cancer.